Chimeric antigen receptor T-cell therapy for stiff-person syndrome: bridging innovation and clinical challenges in neuroimmunology
Open Access
- 1 January 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Abstract
Chimeric antigen receptor T-cells (CAR T-cells) have revolutionized the treatment of hematologic malignancies and are now being explored in autoimmune diseases, including neuroimmunological disorders. The first clinical applications of CAR T-cell therapy for autoimmune diseases have demonstrated promising efficacy, particularly in systemic lupus erythematosus and myasthenia gravis. While CAR T-cell therapy can induce profound B-cell depletion, leading to durable remission, concerns remain regarding cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. However, neuroimmunological conditions with lower target cell burdens may carry a reduced risk of these adverse events. Recent evidence suggests CAR T-cells could offer a transformative approach for stiff-person syndrome (SPS), a rare but debilitating autoimmune neurological disorder characterized by muscle rigidity and spasms. The first reported case of anti-CD19 CAR T-cell therapy in a treatment-refractory SPS patient resulted in substantial clinical improvement, including increased mobility and reduced dependence on symptomatic medication. A newly launched phase II clinical trial (NCT06588491) aims to further evaluate the safety and efficacy of anti-CD19 CAR T-cell therapy in SPS. In this review, we examine the current evidence supporting the use of CAR T-cells in neuroimmunological conditions, discuss the clinical picture and pathophysiological processes associated with stiff person spectrum disorders (SPSD), and elaborate on perspectives and limitations of CAR T-cell therapy in SPSD and beyond.Keywords
This publication has 67 references indexed in Scilit:
- Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transferJournal of Neural Transmission, 2012
- Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibitionBrain, 2010
- Stiff-person syndrome with amphiphysin antibodiesNeurology, 2008
- Advances in the pathogenesis and treatment of patients with stiff person syndromeCurrent Neurology and Neuroscience Reports, 2008
- Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysinThe Lancet, 2005
- High-Dose Intravenous Immune Globulin for Stiff-Person SyndromeNew England Journal of Medicine, 2001
- The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndromeNeurology, 2000
- Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylaseJournal of the Neurological Sciences, 2000
- Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year studyJournal of Neurology, 1999
- PROGRESSIVE FLUCTUATING MUSCULAR RIGIDITY AND SPASM (“STIFF-MAN” SYNDROME): REPORT OF A CASE AND SOME OBSERVATIONS IN 13 OTHER CASESMayo Clinic Proceedings, 1956